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The complex genetic landscape of familial MDS
and AML reveals pathogenic germline variants
Ana Rio-Machin et al.#
The inclusion of familial myeloid malignancies as a separate disease entity in the revised
WHO classification has renewed efforts to improve the recognition and management of this
group of at risk individuals. Here we report a cohort of 86 acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) families with 49 harboring germline variants in 16 pre-
viously defined loci (57%). Whole exome sequencing in a further 37 uncharacterized families
(43%) allowed us to rationalize 65 new candidate loci, including genes mutated in rare
hematological syndromes (ADA, GP6, IL17RA, PRF1 and SEC23B), reported in prior MDS/AML
or inherited bone marrow failure series (DNAH9, NAPRT1 and SH2B3) or variants at novel loci
(DHX34) that appear specific to inherited forms of myeloid malignancies. Altogether, our
series of MDS/AML families offer novel insights into the etiology of myeloid malignancies
and provide a framework to prioritize variants for inclusion into routine diagnostics and
patient management.
https://doi.org/10.1038/s41467-020-14829-5 OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Inherited forms of myeloid malignancies are thought to be rare,although the precise incidence and prevalence are not known.The inclusion of familial myeloid malignancies as a separate
disease entity in the World Health Organization (WHO) classi-
fication of hematological cancers in 20161 and their recognition
by the European Leukaemia Net (ELN)2 has led to greater
awareness of the existence of these heritable forms of disease. It
also highlights the importance of early diagnosis and tailored
management of this group of patients and families3. Not only can
families benefit from appropriate genetic counseling and long-
term surveillance, there are several examples reported in the lit-
erature of donor-derived malignancy following transplant4–6
from an asymptomatic family member and the benefit of mod-
ifying conditioning regimen in patients with an underlying telo-
merase mutation prior to bone marrow transplant7.
The clinical recognition of familial transmission is challenging as
family sizes tend to be small with incidence frequently masked by
marked differences in disease latency and phenotype, exacerbated
by the absence of routine customized familial diagnostic testing.
The problem is more acute in the adult population compared with
pediatric onset of disease, where there can be a heightened suspicion
on behalf of the treating physician and where a malignancy can
arise as part of a wider syndrome3. Many patients/families initially
exhibiting bone marrow failure syndromes such as Fanconi anemia,
dyskeratosis congenita and Shwachman–Diamond syndrome are
prone to the development of myelodysplastic syndrome (MDS) or
acute myeloid leukemia (AML)8.
It is 20 years since inherited variants in the transcription factor
RUNX1 were identified as being responsible for familial platelet
disorder with a propensity to develop AML (FPD-AML)9.
Reflecting the uptake of next-generation sequencing approaches,
we are now aware of more than 20 genes linked with heritable
myeloid malignancies8 (Table 1), with a significant number of
newly described loci appearing restricted to a few core families
(ATG2B/GSK1P10, ETV611,12, SRP7213. Several of these familial
loci are also mutated in sporadic AML/MDS (RUNX19, CEBPA14,
GATA215) while others appear enriched or exclusive to inherited
forms of myeloid malignancies (DDX41 16). These examples offer
a unique insight into the underlying etiology of myeloid malig-
nancies and present opportunities to understand disease latency,
penetrance and the reasons behind the striking intra- and inter-
clinical heterogeneity that is a feature of many of these families.
To address this issue, we have analyzed the largest series of AML/
MDS families assembled to date. It exemplifies the molecular het-
erogeneity of inherited AML and MDS17, with likely pathogenic
variants in 16 previously defined loci, detected in 49 (57%) families.
Whole exome sequencing (WES) in a further 37 “uncharacterized”
families (43%) focus attention on 144 variants in 65 candidate
genes, 26 (40%) of which are mutated in cases of sporadic AML.
This includes genes mutated in rare hematological syndromes
(ADA, GP6, IL17RA, PRF1, and SEC23B), reported in prior MDS/
AML or inherited bone marrow failure (IBMF) series (DNAH9,
SH2B3, and NAPRT1), or novel loci where loss-of- function of the
identified germline variants was demonstrated (DHX34).
Results
Cohort of familial AML/MDS cases. In this study, “familial AML/
MDS” references families where two or more family members
(usually first-degree relatives) were diagnosed with a hematological
disorder (predominantly AML, MDS, aplastic anemia, or throm-
bocytopenia) with at least one of the affected cases being categorized
as MDS or AML. Bone marrow, peripheral blood or other non-
hematopoietic samples were collected from at least one affected
individual from 86 families (FML001-086) and the corresponding
laboratory and clinical information was collated to capture relevant
information relating to patients and their relatives (Table 2; Sup-
plementary Figs. 1 and 2). Our cohort of cases has not been accrued
as part of any systematic initiative, but instead, has been based on
ad hoc referral of cases, which has spanned several years, from both
UK and international institutions. Across our series of 86 families,
we have collated 297 samples corresponding to 221 individuals, of
which 168 were affected and 53 were unaffected (Supplementary
Data 1). In 33 families, material was available on the index case
only. In five additional cases, we have samples on the index case and
at least one additional unaffected individual. In the remaining 48
families, our collection includes samples from multiple affected
individuals allowing us to perform segregation analysis on identified
variants. For simplicity, we have assigned our families into two
discrete groups (Table 1) based on the panel used for clinical
indication “R347 Inherited predisposition to acute myeloid leuke-
mia (AML)” in the NHS England Genomic Medicine Service
[https://www.england.nhs.uk/publication/national-genomic-test-
directories/]. Group 1, where a variant has been detected either at a
locus with high/moderate level of evidence for gene–disease asso-
ciation, is emerging from basic research or is mutated in other
inherited hematological syndromes (FML001-FML049; Fig. 1;
Supplementary Fig. 1; Supplementary Data 2); Group 2, where the
molecular lesion has not been defined (FML050–FML086; Supple-
mentary Fig. 2; Supplementary Data 3).
Group 1 families with variants in established genes. Of the 49
Group 1 families (Fig. 1; Supplementary Fig. 1; Supplementary
Data 2), 32 have been reported as part of previously published
studies9,13,14,18–32. The additional 17 families (Fig. 2; Table 3;
Supplementary Data 4) harbor variants in 13 discrete loci and
together highlight the high index of suspicion needed on behalf of
the treating physician to infer an inherited malignancy
which warrant further investigation. The clinical heterogeneity is
reflected in variations in age of onset from 1 to 68 years, MDS/
AML co-occurring with other non-hematological features in six
families (FML019, FML037, FML041, FML044, FML045, and
FML047) and variable penetrance observed in four families
(FML007, FML014, FML018, and FML041) (Fig. 2; Table 3;
Supplementary Data 2).
Family FML007 represents the second example of a C-terminal
CEBPA germline variant, p.Gln330Argfs*74, that is associated
with reduced penetrant (over 50% of carriers are asymptomatic)
AML (Fig. 2a). This is in contrast to the more conventional near
Table 1 Genetic classification of MDS/AML families.
Group Description Genes Number of
families
Group 1 Families with variants in known genes High level of evidence for gene–disease
association
ANKRD26, CEBPA, DDX41, ETV6,
GATA2, RUNX1, TERC, TERT, TP53
39 (45%)
Moderate level of evidence for gene–disease
association
ACD, CHEK2, RTEL1, SAMD9,
SAMD9L, SRP72
4 (5%)
Genes emerging from basic research or mutated in other inherited
hematological syndromes with high risk of MDS/AML
ATG2B/GSKIP, ERCC6L2, FANC
genes, MBD4, MECOM, SBDS, WAS
6 (7%)
Group 2 Families where the specific gene
variants have not been established
Unknown 37 (43%)
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fully penetrant N-terminal variants33, seen in most examples of
pure familial CEBPA AML. DDX41 variants were detected in
probands from FML012 (p.Met1?) and FML013 (p.Arg124*)
(Fig. 2b, c), with both affected patients diagnosed with MDS at 68
years. The heritable presentation in this family could be easily
overlooked in favor of sporadic disease due to its unusual late
onset17. The heterozygous germline GATA2 variant p.Thr354Met,
present in both the index case (III.1) and his asymptomatic father
(II.2) of family FML018 (Fig. 2e), represents a further example of
reduced penetrance linked to this particular missense GATA2
variant, where variable penetrance has been associated with
fluctuations in the expression of the mutated allele34. The
occurrence of MDS/AML in certain families may also coincide
with other non-hematological features: the index case of family
FML019 presented with MDS and congenital deafness, analogous
to a case reported by Saida et al.35 in a family with identical
germline GATA2 variant (p.Arg362*) (Fig. 2f). In family FML037,
harboring a novel TERC variant n.179_180delinsGG (absent in
ExAC database) (Fig. 2l), both affected individuals (II.2 and II.1)
were prematurely gray in their 20s, a feature frequently associated
with TERC and TERT variants. Our series also includes three
examples of FPD-AML (FML029, FML030, and FML031)
where sequencing analysis failed to detect any RUNX1 variants
(Fig. 2g–i; Supplementary Data 2). Familial platelet disorder with
predisposition to myeloid malignancy (FPDMM) is normally
associated with germline RUNX1 variants and characterized by
life-long moderate thrombocytopenia and platelet function
defects with heterogeneity both in age and presentation and
significant risk of MDS/AML transformation, estimated at
20–60%8. Although most of the FPDMM families harbor
germline RUNX1 variants, inherited large intragenic duplications
or deletions have been also described in these families36–39.
Therefore, we performed a subsequent profiling to detect large
copy number variants and we identified novel germline RUNX1
deletions in the three families with FPD-AML. A RUNX1 deletion
(chr21:36349450–36572837) was detected in patient II.5 of family
FML029 (Fig. 2h; Supplementary Fig. 3a) and confirmed in other
affected family members (III.2, III.3, and III.4) (Supplementary
Fig. 3b). In family FML030, a RUNX1 deletion was observed in
II.2 that was absent in his healthy sister (II.1) (Fig. 2g;
Supplementary Fig. 3). Peripheral blood and salivary DNA from
II.2 of family FML031 revealed a RUNX1 666 kb deletion (chr21:
36389457–37055677) (Fig. 2i; Supplementary Fig. 3). Altogether,
a comparison of breakpoints in the three families revealed a
“hotspot” for constitutional deletion, with a common deleted
segment spanning ~100 kb (chr21: 36400658–36572837) that
encompasses the distal RUNX1 promoter and first two exons.
These results highlight the importance of performing copy
number assessment in families or individuals who present with
an appropriate clinical phenotype.
Identifying new candidate genes in Group 2 families. We
performed WES analysis in the remaining 37 families (FML050–
FML086; EGAD00001004539; Supplementary Fig. 2; Supple-
mentary Data 3) where we had failed to detect a mutation in any
of the Group 1 genes. It is worth noting that we cannot rule out
the possibility that our discovery series includes cases of known
loci where CNVs or non-coding regulatory mutations represent
novel molecular mechanisms which would go undetected using a
coding-only screening strategy, or indeed the co-occurrence of
independent sporadic cases of disease in the same family. In
Group 2, we did not include families where we had assigned a
variant to a category of “variant of unknown significance” (VUS).
In FML014, for example (Fig. 2d), the index case (IV.2) retained
a novel heterozygous germline ETV6 variant c.349C>T (p.
Leu117Phe) with low ExAC frequency (8.237E-06) but samples
from other affected family members (maternal grandfather (II.2),
maternal great aunt (II.3), and maternal great-grandmother (I.2))
who had all died of leukemia were unavailable. This exemplifies
the inherent problems in classifying variants as well as searching
for new loci in families where the molecular lesion has not been
described or when material is limited and there is too great a
reliance on the index case.
Our WES data suggest that there is no single gene that can
account for the large number of unattributed heritable cases in
our series. We observed on average 311 rare single-nucleotide
variants (minor allele frequency <0.005, range 161–781) per
patient. In order to identify variants with a causative role in
familial MDS/AML, we applied the following criteria (Supple-
mentary Fig. 4): (i) demonstrated variant allele frequencies >30%,
(ii) indels (6.2%), nonsense (2.4%), or splicing (±1, 2, or 3) (5.1%)
variants affecting the canonical transcript, (iii) segregated with
the disease where testing was possible, (iv) a frequency of <0.0001
in population controls (ExAC database), (v) predicted to be
pathogenic with two out of four tools used for functional
annotation (PolyPhen2, MutationTaster, SIFT and Provean), and
(vi) detected in the same gene in at least two families. In order to
mitigate the large number of missense variants (86.3%), genes
were only included if missense variants were detected in three or
more families. These criteria defined 130 variants in 52 candidate
genes (Supplementary Data 5). We also took advantage of
other published series, cross-referencing our WES data with the
familial MDS/AML candidate loci selected by Churpek et al.40,
the potential candidate gene in the MDS/AML family described
by Patnaik et al.41 and the causal, likely causal or possibly
contributing genes identified in a cohort of inherited BMF
patients by Bluteau et al.42 (Supplementary Data 6). This has
allowed us to include an additional 13 genes, overlapping with
these previous studies (Supplementary Data 7).
The combination of both criteria resulted in a final list of 144
variants in 65 genes across 34 of the 37 families (Supplementary
Fig. 5; Supplementary Data 8). Multiple variants were detected in the
majority of families (30/37) with no variant observed in FML052,
060, and 066. All variants selected for Sanger sequencing were
validated (n= 48) and segregation analysis confirmed the germline
transmission in all cases tested where material was available from
more than one affected individual (Supplementary Fig. 6). Con-
sistent with the germline origin, the median VAF of all 144 variants
was 0.48. Twenty-six (40%) of the 65 genes were previously reported
to be mutated in at least one example of sporadic AML from
Table 2 Summary of the cohort of MDS/AML families.
Characteristics Number of
families (%)
Clinical phenotype
MDS 12 (14)
AML 17 (19.8)
MDS/AML 18 (20.9)
MDS/AML/TCP 15 (17.4)
MDS/AML/BMF 24 (27.9)
Family history of hematological disease 86 (100)
Consanguinity 3 (3.5)
Other malignancies/disorders
Non-hematological cancers 12 (14)
Neurological disorders 7 (8.1)
Other hematological malignancies (CML,
ALL, non-Hodgkin’s lymphoma)
3 (3.5)
Pulmonary fibrosis 2 (2.3)
Liver disease 2 (2.3)
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TCGA43 and Tyner et al.44 data (frequency ranged from 0.1% to
11%) (Supplementary Fig. 5; Supplementary Data 8).
Following the recent study describing a synonymous GATA2
germline variant affecting RNA splicing in a MDS/AML family45,
for completeness, we also performed an in silico analysis of our
WES results using the Annovar tool46 and the RefSeq Database47
identifying 39 novel splicing synonymous variants (Supplemen-
tary Data 9), none of which arose in either GATA2 or any other
Group 1 loci.
Rationalizing candidate genes into discrete groups. We next
sought to rationalize these 65 candidate genes by dividing them
into two discrete groups based on an association with rare
hematological syndromes (i) and a relevant function and/or
mutated in three or more families (ii) (Supplementary Fig. 4).
Firstly, germline variants in 26 of the selected 65 genes (40%)
have been implicated across a broad range of inherited disorders
(Supplementary Data 8). Notably, five genes with germline
variants in 10 families, ADA, GP6, IL17RA, PRF1, and SEC23B,
have been linked with autosomal recessive hematological syn-
dromes (Fig. 3): T cell-negative, B cell-negative, natural killer
cell-negative severe combined immunodeficiency (ADA, with
novel heterozygous loss of function variants in our families
FML056 (p.Gln3*) and FML071 (p.Glu88Argfs*34)); platelet-
type bleeding disorder-11 (GP6, mutated in families FML055 (p.
Arg159*) and FML063 (p.Met430Lys)); immunodeficiency-51
(IMD51) (IL17RA, with variants in families FML050, FML053,
and FML068); familial hemophagocytic lymphohistiocytosis-2
(FHL2) (PRF1, mutated in family FML085 (p.Glu275Lys) and
one family presented by Bluteau et al.42 (p.Asn252Ser)); and
congenital dyserythropoietic anemia type II (SEC23B, with
variants in families FML061 (p.Pro542Leu) and FML062 (p.
Glu361Asp)) (Fig. 3; Supplementary Data 8).
Among the non-syndromic genes, we noted DNAH9 with
variants in three families, a gene that interacts with the
hematopoietic regulator BCL648 and is also mutated in one of
the families described by Churpek et al.40. In another family we
identified a variant in SH2B3 (p.Ala49Thr), implicated in
hematopoietic stem cell self-renewal and quiescence through
direct interaction with JAK249–51, with the variant adjacent to a
frameshift variant described by Bluteau et al.42(p.Arg50-
Glyfs*147) (Fig. 3). We also noted a germline duplication in
NAPRT1, a major enzyme in cellular metabolism52, in one
additional family (FML064, p.Val216_Phe219dup), highlighting
its candidacy as it was previously found to be mutated (p.
Arg405*) in the affected members of an MDS/AML family
described by Patnaik et al.41 (Fig. 3; Supplementary Data 8). We
also identified three families with variants in TET2, an epigenetic
modifier that is recurrently mutated in sporadic AML and clonal
hematopoiesis of indeterminate potential (CHIP), but whose
germline variants may constitute a predisposing factor for
myeloid neoplasm53. Segregation of TET2 variant in FML054
was demonstrated by Sanger sequencing in individuals I.1 and
II.2 (Supplementary Fig. 6), but we could not discount a CHIP
origin of the TET2 variants in families FML075 and FML081
(VAFs of 0.46 and 0.49, respectively).
Variants in the nonsense-mediated RNA decay regulator
DHX34. Four families harbored heterozygous variants in DHX34
(p.Tyr515Cys, p.Arg897Cys, p.Asp638Asn and p.Glu444Asp), a
RNA helicase that was shown to have a functional role in the
nonsense-mediated RNA decay pathway (NMD)54,55 (Fig. 4a;
Supplementary Data 8). The clinical features of the families
were overlapping, with early disease onset. The index case in
FML071 (II.2; Supplementary Data 3; Supplementary Fig. 2) was
initially found to have thrombocytopenia, which progressed to
Congenital neutropenia/
Shwachman-Diamond syndrome
Familial
MDS/AML
Classical inherited
BMF syndromes
Other inherited syndromes 
associated with 
hematological disease
CEBPA
RUNX1
ETV6
GATA2
ERCC6L2
MECOM
SAMD9L
Pancytopenia/BMF
TERT
TERC
RTEL1
Dyskeratosis congenita
FANCAFanconi anemia
SRP72
WAS
SBDS
Constitutional
thrombocytopenia DDX41
IL17RA
GP6
ADA
Li-Fraumeni syndrome
T(–), B(–), NK(–) severe combined
immunodeficiency
Immunodeficiency-51
Platelet-type bleeding
disorder-11
DHX34
SH2B3
DNAH9
NAPRT1
TP53
Familial hemophagocytic
lymphohistiocytosis-2PRF1
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Fig. 3 Summary of disease genes and new candidate genes mutated in our cohort of MDS/AML families. Schematic representation of established
disease genes (Group 1) and new candidate genes (Group 2) that are mutated in our cohort of MDS/AML families, and their overlap with classical
inherited BMF syndromes based on Bluteau et al. classification42 (blue) or other inherited hematological disorders (pink). In orange font, genes reported
to be frequently mutated in sporadic AML.
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pancytopenia with hypocellular BM and tri-lineage myelodys-
plasia at the age of 10 years. Cytogenetic analysis showed
monosomy 7 in ~10% of BM cells. She died of pulmonary
complications post-SCT. Her older brother (II.1) had a similar
hematological profile, presenting first with thrombocytopenia and
at the age of 5 years had a hypocellular BM, dysplasia, and
monosomy 7. He died at the age of 11 years. In family FML061
(Supplementary Data 3; Supplementary Fig. 2), the index case
(II.1) at the age of 2 years had intermittent neutropenia, anemia
with macrocytosis and thrombocytopenia. The BM cellularity was
reduced with tri-lineage dysplasia and monosomy 7. Her mother
(I.1) was diagnosed with AML (sub-type M5) at the age of 10
years. She was treated successfully with chemotherapy. The index
case in FML065 (II.1; Supplementary Data 3; Supplementary
Fig. 2) at the age of 7 years had pancytopenia and was diagnosed
to have AML with normal karyotype. His father (I.2) had been
diagnosed to have hypocellular myelodysplasia. In the fourth
family (FML055), the index case (II.2) was found to have pan-
cytopenia at the age of 22 years. Bone marrow examination
showed he had acute mixed lineage leukemia which was refrac-
tory to chemotherapy. His older brother (II.1) was diagnosed with
AML at the age of 23 years. He died from complications post-
SCT. Patients with heterozygous DHX34 variants had no extra-
hematopoietic abnormalities and no acquired variants in any of
the 33 genes frequently mutated in MDS/AML analyzed by tar-
geted sequencing, apart from an ASXL1 frameshift insertion (p.
Gly646Trpfs*12) (VAF 12.7% and ExAC frequency of 0.0016)
identified in the index case (II.1) of family FML061. It is
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noteworthy, the index cases of two families (FML061 and
FML071) had monosomy 7 and cytogenetic data were unavailable
for the other two families.
Previously, we have shown that DHX34 is a bona fide NMD
factor that acts in concert with core NMD factors to regulate a
significant number of endogenous RNA targets in C. elegans,
zebrafish, and human cells56,57. DHX34, a member of the DExH/
D box family of RNA helicases, promotes remodeling of
messenger ribonucleoproteins (mRNPs) during NMD. At the
molecular level, DHX34 induces a series of molecular transitions
that result in an increased phosphorylation of the core NMD
factor, UPF1, and leads to an enhanced recruitment of the NMD
factors UPF2 and UPF3 to UPF155,58. These events are required
for targeting aberrant mRNAs for degradation. All four DHX34
variants identified in our families, compromised NMD activity, as
shown by their failure to promote phosphorylation of UPF1 to
levels induced by the wild-type protein (Fig. 4b and c), despite
retaining the ability to bind UPF1 (Fig. 4d). Importantly, we also
show that all four DHX34 variants display a reduced recruitment
of UPF2 and UPF3B to UPF1 (Supplementary Fig. 7).
Discussion
While the coding landscape of somatic cases of myeloid malig-
nancies is complete, we are still some way behind in cataloging the
germline and somatic variants that arise in familial presentations
of these diseases. The inclusion by the WHO of inherited forms of
MDS/AML as an independent entity represented an important
step forward and created a heightened awareness of this group of
at risk individuals1, so that today, with the application of NGS,
more than 20 different loci of varying frequency have been linked
to the occurrence of these familial diseases (Group 1; Table 1).
There is a growing suspicion that the familial occurrence of AML/
MDS is underappreciated clinically3; however, in the absence of
large collections of well annotated cases and comprehensive gene
discovery programs, it will be challenging to define with con-
fidence the precise contribution of this group of patients to MDS/
AML and to optimally manage patients and at risk family mem-
bers. In our study, we have started to address this gap in knowl-
edge by profiling the coding genome in 86 families with a history
of myeloid disease. We report several new predisposing candidate
genes in familial MDS/AML and note a significant overlap
between the genetics of MDS/AML, inherited BMF syndromes
and certain rare hematological syndromes (Fig. 3). These studies
also pinpoint new biological mechanisms that appear to be specific
to inherited forms of myeloid malignancies, including variants in
the RNA helicase, DHX34, detected in four families, which impact
the activity of the NMD pathway.
Overall, the pace of progress in the field of familial AML/MDS
is hindered by the need for robust collection of samples, both
from affected and unaffected family members and of diseased
and healthy tissue, in order to discriminate germline from
somatic changes, and passengers from pathogenic variants.
Access to large multigenerational families is typically rare and
while we have collected material on multiple affected individuals
in many families, a reliance on material from a single index case
remains problematic. While the availability of fibroblasts offers a
gold standard approach to discriminate germline from somatic
changes17, this was not practical in our series, reflecting for the
most part the historical nature of our collections. We relied on
confirming the germline origin of variants by segregation ana-
lysis where material was available from multiple affected indi-
viduals. In some cases, samples were available from a single
affected and unaffected family member, and while these may be
informative, caution is also required since reduced penetrance or
late onset of overt disease is a feature of existing Group 1 loci
that includes the GATA234, DDX4159 and C-terminal CEBPA33
mutations.
The candidate variants arising in our 37 discovery families
exhibit a broad range of biological functions and, in some
instances, have been implicated in malignant and non-
malignant hematological disease (Supplementary Data 8). The
confident prediction of new candidate genes is hindered by the
presence of multiple variants in individual families (3.9 variants
per family on average, range 1–16) and that many of the cor-
responding genes may not have an obvious functional asso-
ciation with hematopoiesis. Some candidate genes have been
linked with hematological syndromes including GP6 (FML055
and FML063), a glycoprotein receptor involved in platelet-
collagen interactions during thrombus formation, mutated in
platelet-type bleeding disorder-1160; SEC23B (FML061 and
FML062), a component of the transport vesicle coat protein
complex II (COPII), mutated in congenital dyserythropoietic
anemia type II (CDAII)61; ADA (FML056 and FML071), a
causative factor of T cell-negative, B cell-negative, natural killer
cell-negative severe combined immunodeficiency62; IL17RA
whose homozygous germline variants are the cause of
Immunodeficiency-51 (IMD51); and PRF1 (FML085) asso-
ciated with familial hemophagocytic lymphohistiocytosis-2
(FHL2). Such variants highlight the phenotypic complexity
that can accompany specific gene variants and it is noteworthy
that in all of these cases the referring center did not observe any
features of immunodeficiency or other gene-specific features.
Overall, it was highly informative to cross-reference our series
of variants with other discovery cohorts of familial MDS/AML
or IBMF syndromes. Bluteau et al.42 reported a variant in
SH2B3, which is a recognized negative regulator of normal
hematopoiesis that is expressed in HSCs and progenitors.
SH2B3 is mutated in 5–7% of myeloproliferative disorders,
lymphoid leukemia and the non-malignant disease idiopathic
erythrocytosis63. The variant in our study (FML085, p.
Ala49Thr), which is adjacent to the one reported by Bluteau
et al.42, locates to the dimerization domain of this adapter
protein and appears distinct from the variants reported in
myeloproliferative neoplasms that predominate in the PH and
SH2 domains63.
No variants met our selection criteria in three families,
FML052, 060, and 066 and these examples highlight perfectly
the challenges faced by researchers in identifying predisposing
lesions. It is conceivable that such families may not represent
bona fide familial disease and instead result from multiple
sporadic examples of disease in the same family. It is also
feasible that the variants may reside outside of the coding
region, as seen with GATA264–66, or reflect CNVs, as shown in
examples of RUNX1 mediated FPD36. Equally, we cannot rule
out the possibility that a variant is private to a particular family;
we would have overlooked the candidacy of NAPRT1 in
FML064 (p.Val216_Phe219dup) were it not for another variant
(p.Arg405*) being recently reported in the same gene in an
MDS/AML family by the group of Patnaik et al.41. This gene
encodes an NAD salvage enzyme and is reminiscent of some of
the recent Group 1 loci, including DDX4116, as having no
immediate functional association to AML/MDS. Such examples
highlight the benefits of pooling data across series of patients
and the importance of international collaborations, in order to
focus attention on specific variants that co-occur across
families, which may in the longer term gain acceptance as a
Group 1 locus, while the validation of rare or private gene
variation will always be challenging.
We functionally validated heterozygous variants in the RNA
helicase DHX34, detected in four families, all of which impacted
activity of the NMD (nonsense-mediated mRNA decay) pathway.
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NMD is a quality-control mechanism that targets mRNAs that
contain premature termination codons for degradation, but also
regulates the expression levels of a large number of naturally
occurring transcripts67. Phosphorylation of the core NMD factor
UPF1 is essential for NMD activation, since this event represses
further translation initiation and triggers mRNA decay68.
Importantly, we show that all four DHX34 variants have a reduced
effect on UPF1 phosphorylation (Fig. 4) and also display dimin-
ished recruitment of UPF2, indicating a decreased NMD activity
(Supplementary Fig. 7). Interestingly, another RNA helicase,
DDX41, is now a recognized locus in familial and acquired cases of
MDS and AML16. DHX34 does, however, belong to a different
family of RNA helicases, the DExH/D type of proteins69, and
besides its reported role in NMD, has also been identified as a
component of the spliceosomal complex C, suggesting its invol-
vement in pre-mRNA splicing70. The reported variants in DDX41
also give rise to defects in pre-mRNA splicing and, given the
prevalence of mutations in pre-mRNA splicing factors in MDS/
AML patients71, one possibility is that splicing defects caused by
mutations in DHX34 may be one way that these germline variants
contribute to pathogenesis.
While this new knowledge may well prove important for the
respective families where awareness may prevent the occurrence
of donor-derived disease following selection of asymptomatic
donors and improve the overall management of this patient
group, it is important not to overemphasize the individual impact
of variants reported in our study. In a broader scheme, resolving
germline predisposition can offer new insights into the etiology of
acute leukemia, seen recently with DDX4116 and SAMD9L72,73
variants, and shed light on the mechanisms that underpin disease
latency, penetrance, and intra-clinical heterogeneity, given that
the disease arises from the same initiating gene mutation. We are
some way off from defining the actual frequency of familial AML/
MDS and in the future, large studies like the HARMONY
Alliance programme (https://www.harmony-alliance.eu/), a Eur-
opean Network of Excellence that is collecting information on
seven hematological malignancies including MDS and AML, may
provide the resources necessary to rationalize patients into dis-
tinct familial and sporadic groups and address the question of the
incidence of these forms of AML/MDS. Altogether, these new
data represent an important step forward in developing tailored
diagnosis for familial MDS/AML while providing insights into the
etiology of myeloid malignancies and a framework on which to
integrate and prioritize genetic variants emerging from research
and predisposing to these diseases.
Methods
Patients and families. Two hundred and twenty-one individuals from 86 families
were included in the study (Supplementary Data 1 and 2; Supplementary Figs. 1
and 2). In each family, two or more family members (usually first-degree relatives)
were diagnosed with a hematological disorder (predominantly AML, MDS, aplastic
anemia, or thrombocytopenia) with at least one of the affected cases being cate-
gorized as MDS or AML. Patients and asymptomatic members of the families
included in the study gave written consent under the approval of our local research
ethics committee (London—City and East, REC reference 07/Q0603/5). Exome
sequencing and candidate gene sequencing were performed using genomic DNA
obtained from whole peripheral blood, bone marrow aspirates, saliva or skin
fibroblasts (Supplementary Data 1).
Targeted sequencing. Targeted sequencing of 10 known disease genes (ACD,
ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72, TERC, and TERT)
was performed for the index case of each family using the accredited testing facility
at the West Midlands Regional Genetics Laboratories (WMRGL) in Birmingham,
UK [https://www.geneadviser.com/genetictest/familial_mds_familial_aml_
sequencing_birmingham]. Variants were considered pathogenic if they had been
previously described to be associated with familial MDS/AML or new variants
(SNVs or indels) meeting the following criteria: (1) minor allele frequency in
healthy population (ExAC and gnomAD databases) <0.00001, (2) variant allele
frequency >30%, (3) predicted to be pathogenic with two out of four tools for
functional annotation (PolyPhen2, MutationTaster, SIFT and Provean), (4) suffi-
cient evidence of pathogenicity and not meeting any criteria for a benign assertion
following ACMG guidelines74, and (5) where practical, the segregation with
affected individuals.
A targeted myeloid panel of 33 genes frequently mutated in MDS/AML (ASXL1
(exon 12), BCOR (all), CALR (exon 9), CBL (exons 7+ 8+ 9), CEBPA (all), CSF3R
(exons 14–17), DNMT3A (all), ETV6 (all), EZH2 (all), FLT3 (exons 14+ 15+ 20),
GATA2 (all), GNAS (exons 8+ 9), IDH1 (exon 4), IDH2 (exon 4), IKZF1 (all),
JAK2 (exons 12+ 14), KIT (exons 2, 8–11, 13+ 17), KRAS (exons 2+ 3), MPL
(exon 10), NPM1 (exon 12), NRAS (exons 2+ 3), PDGFRA (exons 12, 14, 18),
PHF6 (all), PTPN11 (exons 3+ 13), RUNX1 (all), SETBP1 (exon 4), SF3B1 (exons
12 – 16), SRSF2 (exon 1), TET2 (all), TP53 (all), U2AF1 (exons 2+ 6), WT1 (exons
7+ 9) and ZRSR2 (all)) was employed to determine the acquired variants in the
five patients with germline DHX34 variants. An in-house True SeqCustom
Amplicon (TSCA) design (Illumina, San Diego, California, USA) was used for
target enrichment. Pooled library targets were sequenced the MiSeq sequencing
platform. Minimum read depth threshold was 150 reads and lower limit of
sensitivity was 5–10% variant allele frequency (VAF).
Whole-exome sequencing. WES libraries were prepared from 200 ng of genomic
DNA using the Agilent SureSelectXT Target Enrichment System for Illumina
Paired-End Multiplexed Sequencing Library coupled with the Agilent SureSelect XT
Human all exon v6 capture reagent. Libraries were sequenced on a NextSeq
550 sequencer using the high output 300 cycles kit generating 150 bp paired-end
single-indexed reads.
WES data were processed according to the pipeline described in Pontikos
et al.75 available at https://github.com/UCLGeneticsInstitute/DNASeq_pipeline. In
brief, short read data were aligned using Novoalign (version 3.02.08). Variants and
indels were called according to GATK (version 3.5) best practice76. Joint calling
and variant quality score recalibration was performed with a set of 2,500 WES
internal control samples from the UCLex consortium in order to minimize
platform specific variants and artefactual batch effects. The variants were then
annotated using the Variant Effect Predictor77, output to JSON format, post-
processed by a Python script and loaded into a Mongo database. The filtering was
performed using a bespoke R script to filter out variants. An external allele
frequency threshold of less than 0.005 or missing from ExAC and GnomAD was
applied. Variants with a sequencing depth <20 or in segmental duplicated regions
of the genome were also filtered out.
Sanger sequencing. Forty-eight selected variants identified by WES in 23 candidate
genes were validated by Sanger sequencing (Supplementary Fig. 6). PCR reactions to
amplify each variant were performed using 1.1× ReddyMix™ (Life Technologies) and
purified PCR fragments (QIAquick Gel Extraction Kit; Qiagen, Venlo, Netherlands)
were sequenced by GATC Biotech (Eurofins, Ebersberg, Germany). Sequences of the
oligonucleotides used are shown in Supplementary Data 10.
RUNX1 deletions detection: array CGH, SNP array and MLPA. As our targeted
sequencing panel did not capture structural abnormalities, a combination of
comparative genomic hybridization array (Array CGH) or SNP array and Multi-
plex Ligation-dependent Probe Amplification (MLPA) was used to identify
germline RUNX1 deletions in the three families with clinical characteristics of
familial platelet disorder with predisposition to myeloid malignancy (FPDMM)
from our cohort (FML029, FML030 and FML031). A customized 2×400k oligo-
array, Agilent™ was used in families FML029 (II.5) and FML031 (II.2) to analyze
genes where CNAs have been associated with familial MDS/AML and IBMF
syndromes (RUNX1, GATA2, CEBPA, SRP9, SRP14, SRP19, SRP54, SRP68, SRP72,
MPL, DKC1, TERT, TERC, NOP10, NHP2, TINF2, CTC1, C16ORF57, TCAB1).
DNA sample from II.2 of family FML030 was hybridized to the The Affymetrix
Cytoscan HD array according to the manufacturer’s protocols. Copy number
analysis was performed using Affymetrix chromosome analysis suite (CHAS) v 2.1.
An MLPA assay customized for familial MDS/AML loci (P437-A1 Probemix, MRC
Holland) was used for verification and segregation analysis (where possible) of the
novel RUNX1 deletions identified in the three families. Raw data obtained from
each sample were analyzed using Peak Scanner software v1.0 (Applied Biosystems,
CA) (Supplementary Fig. 3).
Telomere length measurement. Telomere length measurement was performed
using a monochrome multiplex quantitative PCR method78. Briefly, the amount of
telomeric DNA (T) and the amount of a single copy gene (S) were quantified in
each genomic DNA sample, using standard curves in a real-time PCR reaction
(Roche LightCycler). This gave a T/S ratio, which is proportional to the telomere
length. Samples were run in quadruplicate and compared to the range of T/S ratios
obtained from 225 heathy controls.
DHX34 functional validation. The plasmids pcG T7-DHX34, pcDNA3-3XFLAG-
UPF1 constructs and siRNA have been described previously55. The DHX34 var-
iants were cloned by PCR amplification, using full-length DHX34, as a template.
Primer sequences are available upon request. For UPF1 phosphorylation and UPF2
and UPF3 recruitment experiments, HEK293T cells grown in six-well plates were
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first transfected with 25 nM of siRNA using Dharmafect I (Life Technologies)
following the manufacturer’s instructions and expanded 24 h later. After 72 h cells
were subsequently transfected with 75 nM siRNA, together with 20 µg of
pcDNA3xFLAG-UPF1, and 20 µg of a plasmid expressing either siRNA-resistant
wild-type or mutant T7-DHX34 protein, also including empty vector controls.
Cells were harvested 48 h later for FLAG-Immunoprecipitation using Anti-FLAG
M2 Affinity Gel (A2220; Sigma-Aldrich). Protein complexes were analyzed by
western blotting and UPF1 phosphorylation was detected using Phospho-(Ser/Thr)
ATM/ATR Substrate (2851; Cell Signaling) antibodies. FLAG-UPF1 levels in the
immunoprecipitations were detected with anti-FLAG (F1804, M2 clone; Sigma-
Aldrich), and further probed with anti-UPF2 (sc-20227; Santa Cruz) and anti-
UPF3B (sc-48800; Santa Cruz) antibodies, as previously described55. Signals were
detected with the ImageQuant LAS 4000 system (GE Healthcare) and quantified
using the ImageQuant TL Software (GE Healthcare). For FLAG-UPF1 and T7-
DHX34 co-Immunoprecipitations, cells grown in six-well plates were transfected
with 1 µg pcIneo-FLAG-UPF1 and 1 µg T7-DHX34 constructs or the corre-
sponding empty vector plasmids. Cells were expanded 24 h after and harvested 48 h
after transfection. FLAG-UPF1 and T7-DHX34 constructs were detected using
anti-FLAG or anti-DHX34 antibodies (non-commercial antibody described pre-
viously by Hug and Caceres)55. All antibodies were used at 1/1000 dilution.
Data availability
The whole-exome sequencing data have been deposited in the EGA database under the
accession code EGAS00001003399. Other datasets referenced during the study are
available from TCGA43 [https://portal.gdc.cancer.gov/projects/TCGA-LAML] and
BeatAML from Tyner et al.44 [http://www.vizome.org/aml/]. The reminder, supporting
the findings of this study, are available within the article and its Supplementary
Information files with information corresponding to individual samples accessible
through the corresponding author, upon reasonable request. Images of uncropped western
blots underlying Fig. 4b and 4d and Supplementary Fig. 7 are provided as a Source Data
File. A reporting summary for this article is available as a Supplementary Information file.
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